3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Turcot syndrome
1
Rhabdoid Tumor
1
Pathologic Complete Response
1
Neuroectodermal Tumors, Primitive
1
Nasopharyngeal Carcinoma
1
Medulloblastoma
1
Lung Neoplasms
1
Esophagitis
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
8
Nivolumab
6
Ipilimumab
3
toripalimab
2
atezolizumab
2
Specimen Handling
2
Celecoxib
2
relatlimab
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
camrelizumab
1
avelumab
1
XELOX
1
Neoadjuvant Therapy
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Interleukin-2
1
Induction Chemotherapy
1
Immunotherapy
1
Immune Checkpoint Inhibitors
1
IMM-101
1
E7777 fusion protein
1
Docetaxel
1
Diffusion Tensor Imaging
1
DNA Mismatch Repair
1
DEAE-Dextran
1
Cyclophosphamide
1
Colonoscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Turcot syndrome
×
Induction Chemotherapy
×
1 year
×
Clear all
NCT07259473
2026-01-07
Pre-CATALIS
Shanghai Zhongshan Hospital
Phase 2
Not yet recruiting
15 enrolled